Drug, across the briefings

Cetuximab across 12 cancers

Cetuximab appears in 12 of the briefings; its FDA label names 2 of those diseases.

Disease	FDA label	Open Targets stage, on which gene	Trials	Active
Colorectal cancer	label names disease	phase 4 on EGFR	186	49
Head and neck cancer	label names disease	phase 4 on EGFR	147	26
Anal cancer		phase 4 on EGFR	6	0
Cervical cancer		phase 4 on EGFR	7	1
Cutaneous squamous cell carcinoma		phase 4 on EGFR	11	6
Esophageal cancer		phase 4 on EGFR	38	4
Gallbladder cancer		phase 4 on EGFR	3	0
Glioblastoma		phase 4 on EGFR	10	3
Lung cancer		phase 4 on EGFR	123	31
Nasopharyngeal carcinoma		phase 4 on EGFR	14	2
Pancreatic cancer		phase 4 on EGFR	58	20
Vulvar cancer		phase 4 on EGFR	—	—

The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.